SVB Leerink cut shares of Viracta Therapeutics (NASDAQ:VIRX – Free Report) from an outperform rating to a market perform rating in a research note issued to investors on Friday, MarketBeat Ratings reports. The brokerage currently has $3.00 price target on the stock, down from their prior price target of $5.00.
Other analysts have also issued research reports about the stock. Oppenheimer reduced their price target on shares of Viracta Therapeutics from $13.00 to $11.00 and set an outperform rating on the stock in a research report on Thursday, May 23rd. Royal Bank of Canada reduced their target price on Viracta Therapeutics from $6.00 to $4.00 and set an outperform rating on the stock in a report on Thursday.
Viracta Therapeutics Stock Down 11.8 %
About Viracta Therapeutics
Viracta Therapeutics, Inc, a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir.
Featured Stories
- Five stocks we like better than Viracta Therapeutics
- How to Evaluate a Stock Before Buying
- This Small Cap Wealth Management Stock Could Provide Big Returns
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- Investing in Travel Stocks Benefits
- MarketBeat Week in Review – 8/12 – 8/16
Receive News & Ratings for Viracta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viracta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.